All In Biotech

NDA 011856 · Pharmacia and Upjohn

Solu-Medrol

Methylprednisolone Sodium Succinate · Injection

Last checked: Nov 20, 2026Latest source record: Nov 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1959

May 18, 1959

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,078

579 Phase 3, 236 recruiting

FAERS reports

46,927

41,904 serious, 8,961 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

Indications and Usage When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 18, 1959 Original approval · Type 2 - New Active Ingredient
5 products under this application
  • SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 125MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • SOLU-MEDROL · METHYLPREDNISOLONE SODIUM SUCCINATE EQ 40MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylprednisolone" as an intervention, any sponsor and status, largest first.

All 2,078 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use8,135
  • drug ineffective4,495
  • fatigue4,349
  • headache4,161
  • pain4,119
  • infusion related reaction4,031
  • nausea3,908
  • pyrexia3,843
  • dyspnoea3,716
  • rash3,258
  • arthralgia3,078
  • diarrhoea3,046

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004620
2005732
2006630
2007782
2008777
2009789
2010995
20111,462
20121,369
2013998
20141,379
20151,856
20161,889
20171,907
20182,094
20193,063
20203,755
20213,426
20224,111
20233,747
20244,357
20253,953
20262,231

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Solu-Medrol (Methylprednisolone Sod Succ)

2024 spending

$19K

Beneficiaries

109

227 claims

Per beneficiary

$174

$10.59 per unit

View as table
YearSpending
2020$58,331
2021$56,062
2022$34,553
2023$30,008
2024$18,937

Part D: Solu-Medrol* (Methylprednisolone Sod Succ/PF)

2024 spending

$330K

Beneficiaries

8,497

14,091 claims

Per beneficiary

$39

$8.22 per unit

View as table
YearSpending
2020$334,958
2021$266,460
2022$235,845
2023$234,841
2024$329,969

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,709 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.